A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

(2016) Kristina H. Young et al.   PLoS One

The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma

(2015) Aaron T. Wild et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy

(2015) Michael J Gough et al.   Immunotherapy

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

(2015) Stuart A. Grossman et al.   Journal of the National Comprehensive Cancer Network

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

(2015) R. Winograd et al.   Cancer Immunology Research

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

(2014) Joseph M. Herman et al.   CANCER

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies

(2014) Jeffrey M Sutton   WORLD JOURNAL OF GASTROENTEROLOGY

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

(2014) A. B. Sharabi et al.   Cancer Immunology Research

Sustained CD4+T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide

(2014) Susannah Ellsworth et al.   OncoImmunology

Chemoimmunotherapy: reengineering tumor immunity

(2013) Gang Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells

(2013) Susannah Yovino et al.   CANCER INVESTIGATION

Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer

(2013) P. J. Schuler et al.   CLINICAL CANCER RESEARCH

Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer

(2013) Jian L. Campian et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated

(2013) Michael D. Chuong et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

(2013) Paula D. Bos et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor

(2013) Marka R. Crittenden et al.   PLoS One

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

(2012) J. B. Mitchem et al.   CANCER RESEARCH

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses

(2012) S. K. Seung et al.   Science Translational Medicine

Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying Cells

(2011) Thomas S. Griffith et al.   IMMUNITY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer

(2010) Anand Mahadevan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Radiation Enhances Regulatory T Cell Representation

(2010) Evelyn L. Kachikwu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

(2010) Michael J. Gough et al.   JOURNAL OF IMMUNOTHERAPY

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY